知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.02 秒)

    PROTEIN BIOMARKERS OF LATE STAGE BREAST CANCER
    2.
    发明申请
    PROTEIN BIOMARKERS OF LATE STAGE BREAST CANCER 审中-公开
    蛋白质乳腺癌生物标志物

    公开(公告)号：US20150005183A1

    公开(公告)日：2015-01-01

    申请号：US13932990

    申请日：2013-07-01

    申请人： David Krizman ,  Marlene M. Darfler ,  Thomas P. Conrads ,  Brian L. Hood

    发明人： David Krizman ,  Marlene M. Darfler ,  Thomas P. Conrads ,  Brian L. Hood

    IPC分类号： G01N33/68

    CPC分类号： G01N33/57415 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/60

    摘要： This patent application discloses and describes proteins found to be differentially expressed between primary tumor breast cancer cells histologicaly defined as early stage (stage 0) breast cancer and primary breast cancer cells histologicaly defined as late stage (stage 3) breast cancer. These proteins can be used either individually or in specific combinations in diagnostic and prognostic protein assays on various biological samples from breast cancer patients to indicate the that a breast cancer patient's cancer is in an early, non-aggressive stage or in a late, aggressive stage. Determination of differential expression of these proteins can also be useful for indicating additional therapies to combat the aggressiveness of late stage breast cancer. The full length intact proteins can be assayed or peptides derived from these proteins can be assayed as reporters for these proteins. These proteins can also be identified as “companion diagnostic” proteins, wherein the differentially expressed proteins that are used as diagnostic and prognostic indicators can also be used as targets for therapeutic intervention of breast cancer. Also disclosed and described herein are isotope labeled versions of peptides from the proteins.

    摘要翻译： 该专利申请公开并描述了被定义为早期阶段（阶段0）乳腺癌的原发肿瘤乳腺癌细胞组织学和定义为晚期（阶段3）乳腺癌的原发性乳腺癌细胞组织学之间差异表达的蛋白质。 这些蛋白质可以在乳腺癌患者的各种生物样品的诊断和预后蛋白测定中单独使用或以特定组合使用，以表明乳腺癌患者的癌症处于早期，非侵袭阶段或晚期侵袭阶段 。 确定这些蛋白质的差异表达也可用于指示其他治疗方法以抵抗晚期乳腺癌的侵袭性。 可以测定全长完整蛋白质，或者可以将这些蛋白质衍生的肽作为这些蛋白质的报告物进行测定。 这些蛋白质也可以被鉴定为“伴侣诊断”蛋白质，其中用作诊断和预后指标的差异表达的蛋白质也可以用作乳腺癌的治疗干预的靶标。 本文还公开和描述的是来自蛋白质的肽的同位素标记形式。

    Contiguous capillary electrospray sources and analytical devices
    3.
    发明授权
    Contiguous capillary electrospray sources and analytical devices 有权
    连续毛细管电喷雾源和分析装置

    公开(公告)号：US07544932B2

    公开(公告)日：2009-06-09

    申请号：US10529967

    申请日：2003-10-20

    申请人： George Janini ,  Haleem J Issaq ,  Timothy D Veenstra ,  Thomas P Conrads ,  Kenneth L Wilkens

    发明人： George Janini ,  Haleem J Issaq ,  Timothy D Veenstra ,  Thomas P Conrads ,  Kenneth L Wilkens

    IPC分类号： H01J49/00

    CPC分类号： H01J49/04 ,  B05B5/0255 ,  B05B5/0533 ,  G01N27/44717 ,  G01N35/1095 ,  H01J49/167

    摘要： Contiguous capillaries useful for separating and electrospraying a fluid comprising analyte and electrolyte are provided. The contiguous capillaries have spray tips at one end of the capillaries and electrically conductive portions in proximity to the spray tips. Methods for making the contiguous capillaries and their use as electrospray sources are also disclosed. Apparatus and methods for conveying analyte ions from the capillaries into analytical instruments, such as a mass spectrometer, are also disclosed. The disclosed contiguous capillaries may be used to carryout electrophoresis separation and electrospray ionization of analytes. Methods for obtaining the mass spectra of macromolecular analytes at concentrations lower than previously possibly are provided using the apparatus and procedures described herein.

    摘要翻译： 提供了可用于分离和电喷雾包含分析物和电解质的流体的连续毛细管。 连续的毛细管在毛细管的一端和靠近喷雾尖端的导电部分具有喷雾尖端。 还公开了制造连续毛细管的方法及其作为电喷雾源的用途。 还公开了将分析物离子从毛细管输送到诸如质谱仪之类的分析仪器中的装置和方法。 所公开的连续毛细管可用于进行分析物的电泳分离和电喷雾电离。 使用本文所述的装置和程序提供了以下可能获得浓度低于以前浓度的大分子分析物的质谱的方法。

    Phosphoprotein binding agents and methods of their use
    5.
    发明授权
    Phosphoprotein binding agents and methods of their use 失效
    磷蛋白结合剂及其使用方法

    公开(公告)号：US06818454B2

    公开(公告)日：2004-11-16

    申请号：US09788286

    申请日：2001-02-16

    申请人： Michael B. Goshe ,  Thomas P. Conrads ,  Timothy D. Veenstra ,  Ellen A. Panisko

    发明人： Michael B. Goshe ,  Thomas P. Conrads ,  Timothy D. Veenstra ,  Ellen A. Panisko

    IPC分类号： C07K122

    CPC分类号： G01N33/6842 ,  G01N33/6803 ,  Y10S530/811 ,  Y10T436/13 ,  Y10T436/24

    摘要： The invention provides reagents and methods for characterizing (i.e., identification and/or quantitation) the phosphorylation states of proteins. Proteins may be post-transcriptionally modified such that they contain phosphate groups at either some or all of their serine, threonine, tyrosine, histidine, and/or lysine amino acid residues. In many cases the extent to which a protein is phosphorylated determines it bioactivity, i.e., its ability to effect cell functions such as differentiation, division, and metabolism. Hence, a powerful tool for diagnosing various diseases and for furthering the understanding of protein—protein interactions is provided.

    摘要翻译： 本发明提供用于表征（即，鉴定和/或定量）蛋白质的磷酸化状态的试剂和方法。 蛋白质可以进行后转录修饰，使得它们在丝氨酸，苏氨酸，酪氨酸，组氨酸和/或赖氨酸氨基酸残基的一部分或全部含有磷酸基。 在许多情况下，蛋白质被磷酸化的程度决定了其生物活性，即其影响细胞功能如分化，分裂和代谢的能力。 因此，提供了用于诊断各种疾病和促进对蛋白质 - 蛋白质相互作用的理解的强大工具。

    PROTEIN BIOMARKERS OF RECURRENT BREAST CANCER
    6.
    发明申请
    PROTEIN BIOMARKERS OF RECURRENT BREAST CANCER 审中-公开
    乳腺癌的蛋白质生物标志物

    公开(公告)号：US20150005182A1

    公开(公告)日：2015-01-01

    申请号：US13932843

    申请日：2013-07-01

    申请人： David Krizman ,  Marlene M. Darfler ,  Thomas P. Conrads ,  Brian L. Hood

    发明人： David Krizman ,  Marlene M. Darfler ,  Thomas P. Conrads ,  Brian L. Hood

    IPC分类号： G01N33/68

    CPC分类号： G01N33/57415 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/60

    摘要： This patent application discloses and describes proteins found to be differentially expressed between primary tumor breast cancer cells that did not give rise to recurrent breast cancer disease after initial diagnosis and primary breast cancer cells that did give rise to recurrent breast cancer disease after initial diagnosis. These proteins can be used either individually or in specific combinations in diagnostic and prognostic protein assays on various biological samples from breast cancer patients to indicate the likelihood that a breast cancer patient's cancer will recur after initial diagnosis and treatment. Determination of differential expression of these proteins can also be useful for indicating additional therapies to combat the likelihood of recurrent breast cancer. The full length intact proteins can be assayed or peptides derived from these proteins can be assayed as reporters for these proteins. These proteins can also be identified as “companion diagnostic” proteins, wherein the differentially expressed proteins that are used as diagnostic and prognostic indicators can also be used as targets for therapeutic intervention of breast cancer. Also disclosed and described herein are isotope labeled versions of peptides from the proteins.

    摘要翻译： 该专利申请公开并描述了在初步诊断后不会引起复发性乳腺癌疾病的原发性乳腺癌细胞和初次诊断后引起复发性乳腺癌疾病的原发性乳腺癌细胞之间发现差异表达的蛋白质。 这些蛋白质可以在乳腺癌患者的各种生物样品的诊断和预后蛋白质测定中单独使用或以特定组合使用，以指示乳腺癌患者的癌症在初步诊断和治疗后将复发的可能性。 确定这些蛋白质的差异表达也可用于指示额外的治疗方法来抵抗复发性乳腺癌的可能性。 可以测定全长完整蛋白质，或者可以将这些蛋白质衍生的肽作为这些蛋白质的报告物进行测定。 这些蛋白质也可以被鉴定为“伴侣诊断”蛋白质，其中用作诊断和预后指标的差异表达的蛋白质也可以用作乳腺癌的治疗干预的靶标。 本文还公开和描述的是来自蛋白质的肽的同位素标记形式。